AzTrials
AzTrials

Spondylitis, AnkylosingPhase 2AS SpA axSpANCT04947579

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

A Phase 2 study testing CC-99677 in people with Spondylitis, Ankylosing, run by Celgene at 63 sites in 8 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Spondylitis, Ankylosing
What is being tested?
CC-99677
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
167 participants
Where
63 sitesin 8 countries
Study dates
25 Aug 2021to 21 Feb 2023
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of Ankylosing Spondylitis (AS) fulfilling the modified New York criteria
  • Active axial disease at Screening and Baseline defined by a Bath Ankylosing
  • Spondylitis Disease Activity Index (BASDAI) score ≥ 4 and Total Back Pain ≥ 4
  • Failed prior treatment with at least 2 NSAIDs for at least 4 weeks each
  • Participant has never received a biologic therapy eg, tumor necrosis factor (TNF) antagonist or monoclonal antibody [mAb] against IL-17A (biologic naive main study), or have taken more than one biologic therapy (biologic-failure substudy) for the treatment of AS

Who cannot join

  • Radiographic evidence of total ankylosis of the spine
  • Clinically significant back pain caused by diseases other than AS
  • Concurrent treatment or treatment within the 6 months prior to Baseline with cell depleting biologic agents
  • Participation in any study of an investigational drug, including those for COVID-19
  • History of malignancy
  • Oral corticosteroids (prednisone or equivalent) > 10 mg/day systemically for ≥ 2 weeks prior to Baseline Visit

Trial locations and contacts

63 sites in 8 countries.

63 sites in 8 countries

United States16 sites
  • Local Institution - 029

    Austin, Texas, 78731

  • Local Institution - 028

    Cleveland, Ohio, 44106

  • Local Institution - 006

    Colleyville, Texas, 76034

  • Local Institution - 004

    Dayton, Ohio, 45417

  • Local Institution - 003

    Duncansville, Pennsylvania, 16635

  • Local Institution - 024

    Flagstaff, Arizona, 86001

  • Local Institution - 019

    Fort Worth, Texas, 76107

  • Local Institution - 021

    Gilbert, Arizona, 58297

  • Local Institution - 008

    Houston, Texas, 77099

  • Local Institution - 005

    Jackson, Tennessee, 38305

  • Local Institution - 002

    Memphis, Tennessee, 38119

  • Local Institution - 022

    Phoenix, Arizona, 95037

  • Local Institution - 009

    Portland, Oregon, 97239

  • Local Institution - 026

    Saint Clair Shores, Michigan, 48081

  • Local Institution - 025

    Tucson, Arizona, 85704

  • Local Institution - 017

    Tustin, California, 92780

Other trials in United States

Poland14 sites
  • Local Institution - 311

    Bialystok, 15-077

  • Local Institution - 315

    Bialystok, 15-351

  • Local Institution - 305

    Bydgoszcz, 85-065

  • Local Institution - 302

    Bydgoszcz, 85-168

  • Local Institution - 301

    Elblag, 82-300

  • Local Institution - 307

    Katowice, 40-282

  • Local Institution - 300

    Krakow, 30-002

  • Local Institution - 308

    Krakow, 30-363

  • Local Institution - 310

    Nowa Sól, 67-100

  • Local Institution - 313

    Onyksowa 10, 20-582

  • Local Institution - 312

    Sochaczew, 96-500

  • Local Institution - 306

    Torun, 87-100

  • Local Institution - 303

    Warsaw, 02-691

  • Local Institution - 309

    Wroclaw, 52-416

Other trials in Poland

Czechia8 sites
  • Local Institution - 205

    Brno, 61141

  • Local Institution - 206

    Ostrava, 702 00

  • Local Institution - 207

    Ostrava, 702 00

  • Local Institution - 201

    Pardubice, 530 02

  • Local Institution - 202

    Prague, 13000

  • Local Institution - 203

    Prague, 140 00

  • Local Institution - 211

    Prague, 148 00

  • Local Institution - 204

    Uherské Hradište, 686 01

Other trials in Czechia

Turkey (Türkiye)8 sites
  • Local Institution - 702

    Adapazarı, 54100

  • Local Institution - 707

    Altındağ/Ankara, 06230

  • Local Institution - 700

    Ankara, 06100

  • Local Institution - 701

    Edirne, 22030

  • Local Institution - 705

    Istanbul, 34098

  • Local Institution - 706

    Izmir, 35100

  • Local Institution - 704

    Karabağlar, 35360

  • Local Institution - 703

    Trabzon, 61080

Other trials in Turkey (Türkiye)

Spain7 sites
  • Local Institution - 604

    A Coruña, 15006

  • Local Institution - 607

    Barcelona, 08035

  • Local Institution - 606

    Córdoba, 14001

  • Local Institution - 605

    Mérida, 06800

  • Local Institution - 601

    Sabadell, 8208

  • Local Institution - 602

    Santiago de Compostela, 15706

  • Local Institution - 603

    Seville, 41013

Other trials in Spain

China5 sites
  • Local Institution - 151

    Guangzhou, 510630

  • Local Institution - 152

    Hangzhou, 310014

  • Local Institution - 153

    Huangpu District, 200000

  • Local Institution - 154

    Shanghai, Shanghai Municipality, 200040

  • Local Institution - 150

    Wuhan, 430030

Other trials in China

Romania4 sites
  • Local Institution - 400

    Brasov, 500283

  • Local Institution - 404

    Bucharest, 011025

  • Local Institution - 402

    Bucharest, 011172

  • Local Institution - 403

    Bucharest, 011172

Other trials in Romania

Germany1 site
  • Local Institution - 900

    Herne, 44649

Other trials in Germany

About this study

Official title: A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects With Active Ankylosing Spondylitis

This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period.

Being tested
CC-99677, Placebo
Keywords
Ankylosing Spondylitis, CC-99677, MK2inhibitor, Spinal Diseases, Bone Diseases, Musculoskeletal Diseases, Arthritis, Joint Diseases
Medical subject headings
Spondylitis, Ankylosing, Spinal Diseases, Bone Diseases, Musculoskeletal Diseases, Arthritis, Joint Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CC-99677Drug

    Oral

  • PlaceboOther

    Oral

Study groups in NCT04947579
Study groupRoleWhat they receive
Administration of CC-99677 150 mg QD POExperimental49 participants will be randomized to CC-99677 150 mg in biologic naive main study
Receives: Drug: CC-99677
Administration of CC-99677 60mg QD POExperimental49 participants will be randomized to CC-99677 60 mg in biologic naive main study
Receives: Drug: CC-99677
Administration of Placebo QD POPlacebo comparator49 participants will be randomized to placebo in biologic naive main study
Receives: Other: Placebo
Administration of CC-99677 150 mg QD PO.Experimental20 participants will be randomized to CC-99677 150 mg in biologic-failure substudy
Receives: Drug: CC-99677
Administration of CC-99677 60mg QD PO.Experimental20 participants will be randomized to CC-99677 60 mg in biologic-failure substudy
Receives: Drug: CC-99677
Placebo additional dose cohortPlacebo comparator10 participants will be randomized to placebo in biologic-failure substudy
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Who Achieve ASAS 20 at Week 12

    Percentage of participants who achieve an improvement in disease activity from baseline of ≥ 20% and ≥ 1 unit in at least 3 of the 4 SpondyloArthritis International Society (ASAS) domains on a scale of 0 to 10, and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining domain on a scale of 0 to 10. Baseline is the last non-missing value on or before the date of the first dose of investigational product. The four ASAS Domains are:

    • Patient Global Assessment of Disease (0 to 10 unit Numerical Rating Scale [NRS]);
    • Total Back Pain NRS;
    • Function (the Bath Ankylosing Spondylitis Functional Index [BASFI] score NRS);
    • Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] NRS Questions #5 and #6 for morning stiffness).

    Measured: Week 12

Secondary outcomes (7)
  1. Percentage of Participants Who Achieve ASAS 40 at Week 12

    Percentage of participants who achieve an improvement in disease activity from baseline of ≥ 40% and ≥ 2 unit in at least 3 of the 4 SpondyloArthritis International Society (ASAS) domains on a scale of 0 to 10, and no worsening at all from baseline in the remaining domain. Baseline is the last non-missing value on or before the date of the first dose of investigational product. The four ASAS Domains are:

    • Patient Global Assessment of Disease (0 to 10 unit Numerical Rating Scale [NRS]);
    • Total Back Pain NRS;
    • Function (the Bath Ankylosing Spondylitis Functional Index [BASFI] score NRS);
    • Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] NRS Questions #5 and #6 for morning stiffness).

    Measured: Week 12

  2. Change From Baseline in Ankylosing Spondylitis Disease Activity Score With CRP (ASDAS-CRP) at Week 12

    ASDAS-CRP is a score of disease activity that combines patient reported assessments of back pain (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] question 2), duration of morning stiffness (BASDAI question 6), peripheral joint pain and/or swelling (BASDAI question 3), general wellbeing, and CRP in a weighted manner. The cut-off values for disease activity states and improvement scores are defined as follows: <1.3 inactive disease, ≥1.3 and <2.1 low disease activity, ≥2.1 and ≤3.5 high disease activity and 3.5 very high disease activity. The minimum clinically important difference (MCID) are defined as: change of at least 1.1 unit for 'clinically important improvement' and change of at least 2.0 units for 'major improvement'. Baseline is the last non-missing value on or before the date of the first dose of investigational product. ASDAS-CRP Formula: 0.12xBack Pain+0.06xDuration of Morning Stiffness+0.11xPatient Global+0.07xPeripheral Pain/Swelling+0.58xln(CRP+1)

    Measured: Baseline and Week 12

  3. Change From Baseline in BASDAI at Week 12

    Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a composite score based on a self-administered survey of six questions using a 0 to 10 unit numerical rating scale (NRS) that assesses five major symptoms of AS during the last week: 1) fatigue; 2) spinal pain; 3) peripheral joint pain/swelling; 4) areas of localized tenderness; 5a) morning stiffness severity upon wakening; 5b) morning stiffness duration upon wakening. To give each of the five symptoms equal weighting, the mean of the two scores relating to morning stiffness is taken. The resulting 0 to 50 score is divided by 5 to give a final 0 to 10 BASDAI score. A BASDAI score of 4 or greater is considered to be indicative of active AS disease. Baseline is the last non-missing value on or before the date of the first dose of investigational product.

    Measured: Baseline and Week 12

  4. Change From Baseline in BASFI at Week 12

    Bath Ankylosing Spondylitis Functional Index (BASFI) is a composite score based on a self administered survey of ten questions using a 0 to 10 unit numerical rating scale (NRS) that assesses degree of mobility and functional ability during the last week. The questionnaire consists of eight questions regarding function in AS and the two last questions reflecting ability to cope with everyday life. The left-hand box of 0 represents "easy," and the right-hand box represents "impossible." The resulting 0 to 100 score is divided by 10 to give a final 0 to 10 BASFI score. A higher BASFI score correlates to reduced functional ability. Baseline is the last non-missing value on or before the date of the first dose of investigational product.

    Measured: Baseline and Week 12

  5. Change From Baseline in the SPARCC SI Joint Score at Week 12

    Change from Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) scores of the sacroiliac joints. The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right [L/R]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. Baseline is the last non-missing value on or before the date of the first dose of investigational product.

    Measured: Baseline and Week 12

  6. Change From Baseline in the SPARCC Spine Score at Week 12

    Change from Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) scores of the total spine. All 23 disco-vertebral units (DVU) of the spine (from C2 to S1) were scored for bone marrow edema. A single DVU has 18 scoring units, and each has score of 0 or 1, bringing the maximum total score to 414, the sum ranges from 0 to 414 with higher scores reflecting worse disease.

    Baseline is the last non-missing value on or before the date of the first dose of investigational product.

    Measured: Baseline and Week 12

  7. Percent Change From Baseline in hsCRP at Week 12

    Percent change from baseline in high-sensitivity C-reactive protein (hsCRP). Baseline is the last non-missing value on or before the date of the first dose of investigational product.

    Measured: Baseline and Week 12

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Jul 2021
  2. Study start25 Aug 2021
  3. Primary completion21 Feb 2023
  4. Study completion21 Feb 2023

Why it stopped: The study has been terminated due to Non-Safety reasons because of lack of efficacy in the short-term acute phase.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
167 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04947579
Sponsor's protocol ID
CC-99677-AS-001
Other IDs
U1111-1265-3951, 2019-004108-37, 2019
Acronym
AS SpA axSpA
Status last verified
Apr 2024
First submitted
23 Jun 2021
Last updated
1 May 2024
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Publications

  • Maksymowych WP, Yeshokumar A, Cerullo E, Lambert RGW, Sliwinska-Stanczyk P, Klimiuk P, Kepich R, Pachai C, Zhu M, Liu J, Landis J, Goti V, Greenberg S. Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis. RMD Open. 2026 May 21;12(2):e006527. doi: 10.1136/rmdopen-2025-006527.

    PubMed 42167889

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing CC-99677 in people with Spondylitis, Ankylosing, run by Celgene at 63 sites in 8 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 1 May 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 63 sites in United States, Poland, Czechia, Turkey (Türkiye), Spain and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 May 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Who Achieve ASAS 20 at Week 12 (time frame: Week 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04947579, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in